CLOT Conversations

Send us a textIn this episode of CLOT Conversations, we sit down with Dr. Marc Carrier to explore a groundbreaking study published in the New England Journal of Medicine on reduced-dose apixaban for cancer-associated venous thromboembolism (VTE). Dr. Carrier breaks down the study's findings, which suggest that a lower dose of apixaban after six months of treatment is just as effective in preventing clot recurrence — and significantly safer in terms of bleeding risk. Tune in for expert insights on how this data could shift clinical practice and improve outcomes for patients living with cancer.Reference:Mahé I, Carrier M, Mayeur D, Chidiac J, Vicaut E, Falvo N, Sanchez O, Grange C, Monreal M, López-Núñez JJ, Otero-Candelera R. Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism. New England Journal of Medicine. 2025 Mar 29.Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Send us a textDrs. Mithoowani and Siegal discuss new expert guidance for managing severe bleeding in patients taking oral anticoagulants, including identifying those at risk, optimizing supportive measures, treating the source of bleeding, and administering reversal agents. It includes discussion of the algorithm for use at the point of care that helps identify patients at risk of adverse outcomes, optimize supportive measures, treat the source of bleeding, and administer anticoagulant reversal or hemostatic therapies.Abstract: http://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-2464-2887 Full text HTML: http://www.thieme-connect.com/products/ejournals/html/10.1055/a-2464-2887 Full text PDF: http://www.thieme-connect.com/products/ejournals/pdf/10.1055/a-2464-2887.pdf Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Dr Tony Wan shares the results of a study that examined the effectiveness of an anticoagulation stewardship program (ACSP) in improving adherence to venous thromboembolism (VTE) prophylaxis guidelines and reducing costs at a Canadian teaching hospital. Here what he has to say about the results and the process of setting up the study in his hospital.Tony Wan, Stephanie J. Garland, Chipman Taylor Drury, Justin Lambert, Joshua Yoon, Melissa Chan, Anticoagulation stewardship: Improving adherence to clinical guidelines and reducing overuse of venous thromboembolism prophylaxis in hospitalized medical patients, Thrombosis Research, Volume 239, 2024, https://www.sciencedirect.com/science/article/pii/S0049384824001622 Donate to Thrombosis Canada: https://thrombosiscanada.ca/donateSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

An insightful conversation with co-authors Dr Thalia Field and Dr Jennifer Mandzia on the Canadian Stroke Best Practices 7th edition, Cerebral Vein Thrombosis. Hear from two of the guideline's authors about the latest recommendations on management of CVT.For a copy of the publication click here: Publication LinkSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Dr Deborah Siegal joins us for a discussion on the recent paper, The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Sub-analysis. In this wide-ranging discussion she reviews the results of the sub-analysis and the need for anticoagulant reversal for acute GI bleeding. This discussion provides her perspective on the issue of bleeding with DOACs and the challenges in patient management.Dr. Deborah Siegal MD MSc FRCPC is a clinician-scientist hematologist (thrombosis medicine) at The Ottawa Hospital, Associate Professor of Medicine and School of Epidemiology and Public Health at the University of Ottawa, and Scientist at the Ottawa Hospital Research Institute.  Her primary research interest is improving the safety of anticoagulant therapy including optimizing the management of anticoagulant-related bleeding complications, restarting anticoagulants after bleeding, perioperative management of anticoagulants, and antithrombotic therapies for ischemic stroke in patients with cancer. Dr Siegal is a member of the board of directors of Thrombosis Canada. Reference:Siegal DM, Forbes N, Eikelboom J, Beyer-Westendorf J, Cohen AT, Xu L, Connolly SJ, Crowther M. The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Subanalysis. Circulation. 2024 Apr 16;149(16):1315-8.https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.123.066933Follow us on Twitter:@ThrombosisCan@debsiegalSupport the Show.https://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

This episode of CLOT Conversations features Dr Sam Schulman (Hamilton) and Dr Michelle Sholzberg (Toronto) discussing the 2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19 of which they were two of the co-authors.While COVID-19 is no longer considered a global emergency, healthcare professionals continue to see critical and non-critical cases regularly. This is particularly the case in locations where medical care is challenging.There was a need to update the 2022 guidelines due to the large number of recently-published studies in the area that were not included in the 2022 edition. Consideration was given to recommendations that could be implemented globally. This is an important update to take into account when encountering patients with sever COVID illness.Reference:Schulman S, Arnold DM, Bradbury CA, Broxmeyer L, Connors JM, Falanga A, Iba T, Kaatz S, Levy JH, Middeldorp S, Minichiello T. 2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19. Journal of thrombosis and haemostasis. 2024 Mar 18.Support the Show.https://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

This podcast episode features Dr. Barbara Gunka and Dr. Siraj Mithoowani discussing their research on how bariatric surgery affects direct oral anticoagulants (DOACs).Bariatric surgery is increasingly used to fight obesity-related health problems. However, these patients often need DOACs to prevent blood clots due to surgery and obesity.The concern is that bariatric surgery might change how the body absorbs DOACs. This could make the medications less effective. There's limited data on long-term DOAC use after bariatric surgery.Dr. Gunka and Dr. Mithoowani's study investigated DOAC levels in patients after bariatric surgery. They looked at patients who received any type of bariatric surgery, took a DOAC for any reason, and had their DOAC levels measured afterwards.Tune in to hear the full discussion about the study's findings and their implications for DOAC use after bariatric surgery.Reference:Gunka, B., Mackenzie, D., Hughes, T., Sardo, L., Bayadinova, J., Siegal, D. M., ... & Mithoowani, S. (2024). Pharmacokinetics of direct oral anticoagulants after bariatric surgery: A retrospective cohort study. Thrombosis Research, 235, 15-17.Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

This podcast features an interview with Laurie Sardo and Julia Bayadinova, experts on Cancer-associated Thrombosis, from Hamilton Ontario, authors of a series of publications in the Canadian Oncology Nursing Journal on Cancer-associated Thrombosis, called Spot the Clot.Laurie Sardo is a Nurse Practitioner in the Thrombosis Service, Department of Hematology at St. Joseph's Healthcare in Hamilton. She graduated with her NP from McMaster University in 2014, and her Doctorate in Nursing Practice from D'Youville University in 2022. Laurie's thesis work focused on patient VTE education in the high-risk cancer population.Her professional interests include patient and staff education and remains active on a number of educational interest groups including the Thrombosis Canada Patient & Family Education committee, the ISTH Nursing committee and the US-based Anticoagulation Forum.ANDJulia Bayadinova, is a nurse practitioner specializing in Thromboembolism, serving both inpatients and outpatients at St. Joseph's Healthcare Hamilton. In 2014, Julia graduated from Ryerson University with a combined Master of Nursing and Primary Care Nurse Practitioner Program, and has since found her passion in Thromboembolism. Her research interest lies in patient education. Julia is currently in pursuit of a Doctorate of Nursing Practice degree at Post University and is completing a thesis on the importance of patient education.In this episode, the two guests review some of the key take-aways from the series of articles. The articles can be accessed here:CAT Series in Canadian Oncology Nursing Journal:The significance of VTE in cancer: Introduction of the ‘Spot the CLOT' serieshttps://www.canadianoncologynursingjournal.com/index.php/conj/article/view/1234Spot the CLOT': What cancer patients want to know https://www.canadianoncologynursingjournal.com/index.php/conj/article/view/1262Spot the CLOT': Awareness of cancer-associated thrombosis in healthcare providershttps://www.canadianoncologynursingjournal.com/index.php/conj/article/view/1277/1067Spot the CLOT: Treatment considerations for CAThttps://www.canadianoncologynursingjournal.com/index.php/conj/article/view/1372Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

In Season 2, Episode 2 of CLOT Conversations from Thrombosis Canada, Dr. Tzu-Fei Wang, an associate professor and hematologist, discusses a recent study titled "The prevalence of relevant drug-drug interactions and associated clinical outcomes in patients with cancer-associated thrombosis on concurrent anticoagulation and anticancer or supportive care therapies." The study aimed to investigate drug-drug interactions (DDIs) between anticoagulants and other medications in cancer patients and their impact on clinical outcomes.High Risk of DDIs: The study found that approximately 41% of cancer patients on anticoagulation therapy had relevant drug-drug interactions, particularly with antidepressants and certain other medications.Overall, the study highlights the importance of assessing and managing drug-drug interactions in cancer patients receiving anticoagulation therapy, while also suggesting that not all DDIs necessarily lead to adverse clinical outcomes. Collaborative efforts and larger data sets are needed to better understand and address this complex issue.Reference: Wang TF, Hill M, Mallick R, Chaudry H, Unachukwu U, Delluc A, Carrier M. The prevalence of relevant drug-drug interactions and associated clinical outcomes in patients with cancer-associated thrombosis on concurrent anticoagulation and anticancer or supportive care therapies. Thrombosis Research. 2023 Nov 1;231:128-34.  https://www.sciencedirect.com/science/article/pii/S0049384823002815 Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

The CLOT Conversation Hosts (Dr Jameel Abdulrehman and Dr Maha Othman) discuss Post-Thrombotic Syndrome and the TILE study with two of the authors of the recently published paper, Tinzaparin Lead-in to Prevent the Post-Thrombotic syndrome study protocol, Dr Jean-Phillippe Galanaud and Dr Ilia Makedonov. In the interview the authors discuss the latest research on PTS and the rationale for the TILE study.Dr Jean-Philippe Galanaud is a General Internal Medicine specialist and Thrombosis Physician. He works as a staff physician in the Department of Medicine at Sunnybrook Health Sciences Centre in Toronto; He is associate Professor of Medicine at the University of Toronto.His areas of expertise in research are in the field of the post thrombotic syndrome and of distal DVT; He is currently conducting, with Susan Kahn from McGill, 2 multicentre studies in the field of PTS; 1 on the prevention of post thrombotic syndrome with LMWH (The Tile study) and 1 on the treatment of post thrombotic syndrome with venoactive drugs (The MUFFIN study)AndDr Makedonov completed medical school at the University of Toronto, followed by internal medicine residency in Ottawa. He took a keen interest in thrombosis, doing a fellowship at Sunnybrook and receiving a grant from CanVECTOR. He research has focused on the post thrombotic syndrome as well as distal DVT and cerebral venous sinus thrombosis. He runs a thrombosis clinic at the Southlake Regional Health Centre. He has a broad clinical practice, including peri-partum and cancer associated VTE. In his spare time , he bikes and sails. He hopes to one day own a dog. Reference:  Makedonov I, Kahn S, Abdulrehman J, et al. TILE pilot trial study protocol: Tinzaparin Lead-in to Prevent the Post-Thrombotic syndrome study protocol. BMJ Open 2023;13:e064715. doi:10.1136/ bmjopen-2022-064715  Follow us on twitter: @thrombosiscan Check out our website: https://thrombosiscanada.caSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

 Dr Vicky Mai presented multiple times at the ISTH 2023. Dr Le Gal talks to her about the research that she presented and the implications. The first study that she presented was a systematic review with metaanalysis on thrombolysis in intermediate high and high risk PE. The second one was an abstract on a sub analysis of the PREDICTORS study which looked at the risk of recurrent VTE in patient who presented with a suspicion of recurrent VTE on anticagulation. And there's two projects on COPD exacerbation and pulmonary embolism. Join us on Twitter:@thrombosiscan@VickyMai@grelegalVisit www.thrombosiscanada.ca for more information and resourcesSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Dr Abdulrehman interviews three researchers working in Canada who presented work at ISTH 2023 in Montreal. Dr Menal Huroy, reviews her poster on The Impact of GI Surgeries on peak plasma anti-Xa Direct Oral Anticoagulant levels, Dr Adam Suleman discusses his research on The Risk iof VTE in Primary CNS Lymphoma: A Systematic Review and Dr Ismail Raslan discussed his research, Anticoagulation Post-Pulmonary Endarterectomy: A Retrospective Cohort Study. Three quick interviews covered in 11 minutes!Follow us on Twitter:@thrombosiscanSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Join us for an in-depth conversation with Dr Lucia Caiano and Dr Tzu-Fei Wang, two of the authors of a review exploring the potential role of statins in preventing post-thrombotic syndrome (PTS), a frequent long-term complication of deep vein thrombosis (DVT). They dive into their systematic review and meta-analysis, discussing the intriguing findings drawn from 1971 screened records. The interview reveals their insightful interpretations of data, including the possible 22% reduction of PTS incidence with statin use. Yet, they also acknowledge the limitations seen in randomized controlled trials (RCTs). The conversation offers an invaluable opportunity to better understand the challenges of PTS prevention, the promising role of statins, and the crucial need for larger RCTs to confirm these findings. Don't miss this chance to gain expert insights into this rapidly developing field of medical research.Contact us on Twitter:@ThrombosisCan@TzufeiWangRef:Caiano L, Drury T, Zahrai A, Wang TF, Siegal DM, Rodger MA, Fournier K, Delluc A. Role of statins in the prevention of post-thrombotic syndrome after a deep venous thrombosis event: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis. 2022 Dec 22.Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

In this episode of CLOT Conversations we interview Dr Saskia Middeldorp and Dr Hanke Wiegers, authors of the groundbreaking Highlow study. This open-label, multicenter, randomized controlled trial aimed to determine the optimal dose of low-molecular-weight heparin (LMWH) for pregnant and postpartum women with a history of venous thromboembolism (VTE). Discover the study's findings on the incidence of recurrent VTE, major bleeding, and death from any cause between the intermediate-dose (ID) and low-dose (LD) LMWH groups. The results may surprise you and highlight the need for individualized dosing strategies for pregnant and postpartum women to balance the risks and benefits of anticoagulant therapy. Don't miss this fascinating episode!Dr Saskia Middeldorp is Professor of Medicine and Head of the Department of Internal Medicine of the Radboud University Medical Center in Nijmegen, The Netherlands. Prior to her transfer to Nijmegen in January 2021, she has been a professor of Medicine at Amsterdam University Medical Centers for over 10 years, leading the clinical thrombosis and haemostasis research lines of the Department of Vascular Medicine. Since January 2023, Saskia Middeldorp is one of the 4 Research Domain Leaders in the Radboudumc Research Institution for Medical Innovation.Her present research focuses on several aspects of hereditary and acquired thrombophilia, women's issues in thrombosis and haemostasis, and the clinical evaluation of new anticoagulants and antidotes.Dr Hanke Wiegers is an MD, PhD student, at the department of vascular medicine at the Amsterdam UMC, location AMC. In June 2019 she started her PhD trajectory under the supervision of Prof. Dr. S. Middeldorp as supervisor and focuses particularly on women & thrombosis. On the 17th of March 2023 she will defend her PhD thesis entitled: “Progress in prevention and prediction of venous thromboembolism in women – focus on pregnancy and the postpartum period.”  Hanke Wiegers started as a gynecologist in training on the 1st of January 2023 Bistervels, I. M., Buchmüller, A., Wiegers, H. M., Áinle, F. N., Tardy, B., Donnelly, J., ... & Zelis, M. (2022). Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial. The Lancet, 400(10365), 1777-1787 Follow us on Twitter:@thrombosiscan@MiddeldorpSSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Don't miss our latest podcast interview with Dr Joseph Shaw and Dr Tzu-Fei Wang who discuss insights from their single-center retrospective cohort study, which included 264 patients with nonvalvular AF and Cancer undergoing 302 periprocedural interruptions. Learn about the primary endpoints, which were the 30-day risks of arterial thromboembolism and major bleeding, and the results that showed relatively low risk for these complications when patients were managed according to commonly applied perioperative management recommendations. Tune in now to gain valuable knowledge on this important topic.Aziz, Joseph, et al. "Thrombotic and Bleeding Outcomes Following the Perioperative Interruption of Anticoagulation Among Patients with Non-Valvular Atrial Fibrillation and Active Cancer." Journal of Thrombosis and Haemostasis (2022).Follow us on TwitterDr Shaw: @JRand083Dr Wang: @TzufeiWang@thrombosiscanada.cawww.thrombosiscanada.caSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

In this interview, two of the authors of the paper Direct oral anticoagulants vs vitamin-K antagonists in thrombotic antiphospholipid syndrome: meta-analysis of randomized controlled trials, Dr Jean Connors and Dr Benhood Bikdeli, provide listeners with an overview of their systematic review and meta-analysis that evaluated the efficacy and safety of direct oral anticoagulants (DOACs) compared to vitamin K antagonists (VKAs) in patients with thrombotic antiphospholipid syndrome. The authors searched through three databases (PubMed, EMBASE, and Cochrane Central Register of Controlled Trials) and found four eligible randomized controlled trials with a total of 472 patients. Our podcast guests discuss the results of the study and the clinical implications.  About our guests:Dr Jean M Connors: Jean M. Connors, MD is a hematology attending at Brigham and Women's Hospital and Dana-Farber Cancer Institute; the Medical Director of the Anticoagulation Management Services, and the Hemostatic Antithrombotic Stewardship Program; and an Associate Professor of Medicine at Harvard Medical School. She received a medical degree from The Johns Hopkins University in Baltimore, completed her residency in internal medicine at Beth Israel Deaconess Medical Center in Boson, as well as fellowships in transfusion medicine and hematology & oncology from Brigham and Women's Hospital.Dr. Connors is an Associate Editor for the Journal of Thrombosis and Haemostasis and the Journal of the American College of Cardiology: Basic to Translational Science. She is a member of or holds a leadership role in many professional societies, including ASH and ISTH. She has participated in numerous clinical trials for patients with venous thrombosis in cancer, and anticoagulation questions in general.Dr Benhood Bikdeli:Behnood Bikdeli, MD, MS is a clinician-investigator, with training in cardiology and in vascular medicine who is particularly interested in thrombotic diseases. He is an Associate Physician in the Division of Cardiovascular Medicine at Brigham and Women's Hospital, an Instructor in Medicine at Harvard Medical School, and an investigator at Yale Center for Outcomes Research and Evaluation (CORE). His research has been funded by the NIH, the American Heart Association, Brigham and Women's Hospital and others. Dr Bikdeli has coauthored over 180 publications, which have been published in journals including Lancet, JAMA, JAMA Internal Medicine, Circulation, Journal of the American College of Cardiology, the British Medical Journal, and others. Dr. Bikdeli was the lead author of two international consensus documents related to thrombosis in COVID-19, is the joint principal investigator of the INSPIRATION/ INSPIRATION-S randomized controlled trial, and is an Associate Editor for Thrombosis Research. Ref:Khairani, C. D., Bejjani, A., Piazza, G., Jimenez, D., Monreal, M., Chatterjee, S., ... & Bikdeli, B. (2022). Direct oral anticoagulants vs vitamin-K antagonists in thrombotic antiphospholipid syndrome: meta-analysis of randomized controlled trials. Journal of the American College of Cardiology.Follow us on Twitter:@thrombosiscan@connors_mdSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Are you curious about how to improve the safety and effectiveness of anticoagulant prescriptions for hospitalized patients? Join us for an exclusive interview with two of the authors (Dr Maral Koolian and Pharmacist Ryan Kerzner ) of a groundbreaking study on anticoagulation stewardship program at the Montreal Jewish General Hospital. Our guests will share their findings on the success rate of recommendations made by a multidisciplinary team of physicians and pharmacists, as well as the most common types of adjustments made to prescriptions. Don't miss this opportunity to learn more about the potential benefits of these programs and the future research needed to fully understand their impact on patient outcomes. Download this episode today!Koolian, M., Wiseman, D., Mantzanis, H., Kampouris, N., Kerzner, R. S., & Kahn, S. R. (2022). Anticoagulation stewardship: Descriptive analysis of a novel approach to appropriate anticoagulant prescription. Research and Practice in Thrombosis and Haemostasis, 6(6), e12758. Guest Biographies: Dr Maral Koolian is an Assistant Professor of Medicine and the Director of the Adult Thrombosis Medicine AFC program at McGill University. She is a member of the Division of General Internal Medicine and the Centre of Excellence in Thrombosis and Anticoagulation Care (CETAC) at the Jewish General Hospital. She earned her medical degree at McGill University, where she subsequently completed post-graduate subspecialty training in General Internal Medicine. She then completed a 1-year clinical thrombosis fellowship at the University of Ottawa, followed by an MSc in Quality Improvement and Patient Safety at the University of Toronto. Her main research focus is quality improvement principles as they apply to venous thromboembolic disease and anticoagulation management. Ryan Kerzner graduated with a Bachelor of Pharmacy and a Masters in hospital pharmacy from the Université de Montréal. He has been a pharmacist at the Jewish General Hospital in Montreal since 2008. He is one of the co-founders of the hospital's Antimicrobial Stewardship programs, in which he is still actively involved. He also works in Internal Medicine where he developed an interest in Thrombosis medicine. He officially joined the hospital's CETAC team in 2019, which is the Centre of Excellence in Thrombosis & Anticoagulation Care. In CETAC, with Dr Koolian and 2 other thrombosis pharmacists, he was involved in the development an Anticoagulation Stewardship Program. Follow us on Twitter@thrombosiscan@MKoolian@Pharmacist_MTLCheck out the resources on https://thrombosiscanada.caSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

In this episode we interview two of the authors of a recent paper, Diagnosis and management of severe congenital protein C deficiency (SCPCD): Communication from the SSC of the ISTH, Dr Maha Othman and Dr Leonardo Brandao on this paper from the Journal of Thrombosis and Haemostasis. 2022;20:1735–1743. Severe congenital protein C deficiency (SCPCD) is rare and there is currently substantial variation in the management of this condition. A joint project by three Scientific and Standardization Committees of the ISTH was developed to review the current evidence and help guide on diagnosis and management of SCPCD.About our guests:Dr. Maha Othman is a clinical pathologist/hematologist with specialized training in haemostasis laboratory testing and molecular genetics of bleeding disorders. She obtained her medical degree and MSc in Clinical Pathology in Mansoura University in Egypt. She then completed her PhD in Pathology from Southampton University, UK. After this, she pursued post-doctoral research training in molecular genetics of hemophilia and von Willebrand disease with Dr. David Lillicrap, at Queen's University, Canada. Dr. Othman is currently a full Professor at the School of Medicine, Queen's University and at St Lawrence College, Kingston, Ontario. Her research interests include the clinical and molecular aspects of von Willebrand disease and platelet disorders particularly PT-VWD, and thromboelastography assessment of coagulopathies in women, pregnancy and cancer. She has more than 100 research papers and her research is recognized internationally. She is an editor for Seminars in Thrombosis and Haemostasis and Research and Practice in Thrombosis and Haemostasis Journals. She is a reviewer for a number of Haemostasis journals and a member of several scientific organizing committees on women's health, and advisory boards for international haemostasis conferences. She is the previous Chairman of the Scientific and Standardization Committee (SSC) on Women's Health Issues in Thrombosis and Haemostasis of the ISTH and currently CO-Chair on the SSC for DIC. She is a passionate educator and mentor and an advocate for rare bleeding disorders and bleeding and clotting disorders in women.Dr. Leonardo Brandão  is a native Brazilian who joined the staff at The Hospital for Sick Children in 2004. Since 2019, he has been the Thrombosis Program director. He obtained his medical degree at the University of São Paulo (USP) School of Medicine (FMUSP) before moving to North America, where he completed his post-graduate training (Paediatrics Residency at Emory University, Atlanta/GA, Paediatric Haematology/Oncology fellowship at St. Jude Children's Research Hospital, Memphis/TN, and a second fellowship in Paediatric Coagulation at Weill Cornell University, New York/NY). After finishing his training, he moved to Canada to focus on the field of paediatric thrombosis at SickKids. He is the past-chair of the thrombosis committee for the Canadian Pediatric Thrombosis Hemostasis Network (CPTHN), past-Canadian representative-elect for the Hemostasis and Thrombosis Research Society (HTRS), past-member of the first paediatric venous thromboembolism panel for the American Society of Hematology (ASH), past-co-chair of the paediatric thrombosis subcommittee for the International Society on Thrombosis and Hemostasis (ISTH), and a member of Thrombosis Canada. Links:Thrombosis Canada Clinical Guide:Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Two of the co-authors (Dr Jameel Abdulrehman and Dr Leslie Skeith) of the recently published review and meta-analysis, "Recurrence after stopping anticoagulants in women with combined oral contraceptive-associated venous thromboembolism: A systematic review and meta-analysis" (https://doi.org/10.1111/bjh.18331) discuss the clinical relevance of the results and implications for managing risk for women who have experienced a VTE while on combined oral contraceptives. Dr. Jameel Abdulrehman is a Hematologist and clinician investigator with specialization in Thrombosis and Hemostasis at the Toronto General Hospital within the University Health Network and assistant professor at the University of Toronto. He completed medical school at the University of Alberta, Internal Medicine residency at Western University, Hematology residency at the University of Alberta, a fellowship in thrombosis and hemostasis at the University of Toronto, and a masters in clinical epidemiology at McMaster University. He is an early career investigator with research interests in clinical studies in the use anticoagulation in special populations. He is also the regular co-host of this podcast. And Dr Leslie Skeith:Dr. Leslie Skeith is a Associate Professor in the Division of Hematology & Hematological Malignancies at the University of Calgary. She completed her medical school and Hematology residency training at the University of Calgary, and completed a 2-year fellowship in Thrombosis Medicine at the University of Ottawa. Dr. Skeith's research interest is in the area of pregnancy and venous thromboembolism, as well as medical education. She is currently completing a Master of Health Professions Education (MHPE) degree at the University of Chicago at Illinois (UIC).Follow us:@thrombosiscan@leslieskeithReference:Abdulrehman J, Elbaz C,Aziz D, Parpia S, Fazelzad R, Eischer L, et al. Recurrence after stopping anticoagulants in women with combined oral contraceptive-associated venous thromboembolism: A systematic review and metaanalysis. Br J Haematol. 2022;00:1–13. https://doi.org/10.1111/bjh.18331Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

In this episode we will be discussing a recent paper published in CHEST entitled Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline with lead author Dr Jim Douketis. Dr. Douketis is Staff Physician in General Internal Medicine and Clinical Thromboembolism at St. Joseph's Healthcare Hamilton. He is a Professor of Medicine and holds the David Braley-Nancy Gordon Chair in Thromboembolic Disease at McMaster University. Dr Douketis is past-president of Thrombosis Canada.Dr. Douketis' research interests include perioperative antithrombotic therapy, prognosis of patients with venous thromboembolism, hormonal therapy and thrombosis, prevention of venous thrombosis in medical patients, and clinical practice guideline development.Dr. Douketis is a Fellow of the Canadian Academy of Health Science, Past-President of Thrombosis Canada, Associate Editor of McMaster Textbook of Internal Medicine, Editor-in-Chief of Canadian Journal of General Internal Medicine, Deputy Editor of Annals of Internal Medicine ACP Journal Club, and Associate Editor of Thrombosis and Haemostasis. He has over 350 peer-reviewed publications.Follow us on Twitter;Thrombosis Canada: @ThrombosisCanReference:Douketis JD, Spyropoulos AC, Murad MH, Arcelus JI, Dager WE, Dunn AS, Fargo RA, Levy JH, Samama CM, Shah SH, Sherwood MW. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2022 Aug 11.Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

In this episode have a conversation with Dr Matthew Nicholson and Dr Noel Chan on their recent publication from Blood Review entitled No apparent association between mRNA COVID-19 vaccination and venous thromboembolism (https://www.sciencedirect.com/science/article/pii/S0268960X22000443) which was co-authored by Dr Hadi Goubran and Dr Deborah Siegal.Dr. Matthew Nicholson is a Clinical Hematologist at the Saskatoon Cancer Centre and an Assistant Professor in the College of Medicine at the University of Saskatchewan. He obtained his MD and Internal Medicine residency at the University of Saskatchewan in Saskatoon. Dr. Nicholson completed his Hematology fellowship training at the University of British Columbia in Vancouver and completed a clinical fellowship in thrombosis medicine through McMaster University, and is board certified in Internal Medicine and Hematology. Dr. Nicholson has acted as an advocate for improved training conditions for medical students and residents during his time with provincial health organizations and the resident doctors of Canada board. He co-authored the resident Doctors of Canada "Data Collection and Learner Privacy Principles" which have been adopted to help govern learner privacy rights in medical colleges and medical licensing bodies across Canada.His research interests include Venous Thromboembolism (VTE), thromboprophylaxis, and hemophagocytic lymphohistiocytosis (HLH).ANDDr Noel Chan, is an Assistant Professor in the Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton ON, Canada, specializing in anticoagulant therapy and thrombosis medicine. His research seeks to improve our understanding of the triggers for thrombosis (including the role of inflammation) and the determinants of variable response to antithrombotic therapies to inform on novel strategies with the potential to further reduce the burden of thrombosis.Follow us on Twitter:Dr Matthew Nicholson: @Matt_BloodMDThrombosis Canada: @ThrombosisCanReference:Nicholson, M., Goubran, H., Chan, N., & Siegal, D. (2022). No apparent association between mRNA COVID-19 vaccination and venous thromboembolism. Blood Reviews, 100970.Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

This episode recorded at the ISTH2022 meeting in London features interviews with Dr Rita Selby and Dr James Douketis with Dr Jameel Abdulrehman. Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Thrombosis Canada members Mark Crowther and Taylor Drury join host Jameel Abdulrehman in a discussion on some highlights from the 2022 ISTH meeting in London. Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Thrombosis Canada members Jameel Abdulrehman, Tsu-Fei Wang, Marc Carrier, Joseph Shaw and Yan Xu discuss their highlights from day 2 of the ISTH 2022 program. Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

The 2022 International Society on Thrombosis and Haemostasis (ISTH) annual meeting is the first fully in-person meeting since the start of the pandemic in 2020. A number of Thrombosis Canada members are attending sessions throughout the program and we have invited those who can, to share their insights from the sessions that they think are key with our podcast audience. These short podcasts will give you a taste of some of the interesting information coming from researchers on a range of thrombosis-related topics.Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

In this episode we discuss a recent paper published in The Canadian Journal of Cardiology entitled Canadian Cardiovascular Society 2022 Guidelines for Peripheral Arterial Disease and co-authored by a national team of Canadian expertsWe are joined today by the two of the authors, Dr Sonia Anand and Dr. Eric KaplovitchDr. Sonia Anand is Professor of Medicine and Epidemiology, and a Vascular Medicine specialist at Hamilton Health Sciences. She holds the Canada Research Chair in Ethnic Diversity and Cardiovascular Disease (Tier 1) and is the Heart and Stroke Foundation of Ontario/Michael G DeGroote Chair in Population Health Research. Dr. Anand is a senior scientist at the Population Health Research Institute, and Director of the Chanchlani Research Centre, McMaster University. Her research focuses on the environmental and genetic determinants of vascular disease in populations of varying ancestral origin, women and cardiovascular disease, and peripheral artery disease. Dr. Anand graduated as a Doctor of Medicine from McMaster University in 1992. She completed internal medicine training at McMaster University and a Fellowship of the Royal College of Physicians and Surgeons of Canada, Ottawa, in 1996. Dr. Anand completed a thrombosis fellowship in 1997-98 under the supervision of Dr. Jeffrey Ginsberg at McMaster University, and Vascular Medicine Fellowship under the supervision of Dr. Mark Creager at the Brigham and Women's Hospital, Harvard University, Boston, USA in 2000-01. Dr. Anand received her Master's degree in clinical epidemiology in 1996 and PhD. in Health Research Methodology in 2002 under the supervision of Dr. Salim Yusuf, both at McMaster University. Dr. Anand was Principal Investigator of the WAVE trial in peripheral artery disease (PAD) patients, is the PAD Lead Investigator of the COMPASS trial, and is an executive committee member of the VOYAGER PAD trial. Dr. Anand's large-scale research programs include multi-centre prospective cohort studies and randomized trials. She has published more than 400 peer-reviewed, high-impact papers. In 2019 Dr. Anand was inducted as a Fellow to the Canadian Academy of Health Sciences. In 2021-22 Dr. Anand Co-chaired the Canadian Cardiovascular Society Peripheral Artery Disease Guidelines.ANDDr. Eric Kaplovitch completed his Internal Medicine training at the University of Toronto before completing additional Vascular Medicine and Thrombosis training at both McMaster University and the University of Toronto, as well as a subsequent fellowship at the HoPingKong Centre of Excellence with a focus on new models of care for patients with arterial and venous disease states. He currently practices Thrombosis and Vascular Medicine at the University Health Network and the Sinai Health System in Toronto and serves as the Quality and Safety Lead for the Blood Disorders program. Dr. Kaplovitch's current academic interests include optimizing the choice and intensity of vascular protective agents following severe vascular events, the organization of vascular care within local and regional health systems, as well as the teaching of vascular medicine and thrombosis to front-line clinicians. He served as co-lead for the antithrombotics section of the recent CCS guidelines on peripheral arterial disease. Follow us on Twitter: Thrombosis Canada: @thrombosiscanDr Sonia Anand: @DrSoniaAnand1Dr Eric Kaplovitch: @kaplovitchSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

In this episode we discuss a recent paper published jointly in The American Journal of Gastroenterology and the Journal of the Canadian Association of Gastroenterology entitled American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period and co-authored by a Canada – United States team of experts.The interview with co-authors Dr Alan Barkun and Dr Jim Douketis covers the rationale for the new guidelines as well as the implications for clinicians. Dr Barkun is Professor of Medicine in the Division of Gastroenterology at McGill University and the McGill University Health Centre, Montréal, Canada. He is current holder of the DG Kinnear Chair in Gastroenterology at McGill University. Recipient of many national and international awards, Dr. Barkun has published over 400 peer-reviewed articles and abstracts and has given over 600 international presentations on emerging digestive endoscopic technologies, with an emphasis on methodological, clinical and cost-effectiveness trials of treatments for upper gastrointestinal bleeding (UGIB), bilio-pancreatic diseases and colorectal cancer screening. He is also the current President of the colorectal Cancer screening implementation committee for the province of Quebec. ANDDr. Douketis is Staff Physician in General Internal Medicine and Clinical Thromboembolism at St. Joseph's Healthcare Hamilton. He is a Professor of Medicine and holds the David Braley-Nancy Gordon Chair in Thromboembolic Disease at McMaster University. Dr Douketis is past-president of Thrombosis Canada.Dr. Douketis' research interests include perioperative antithrombotic therapy, prognosis of patients with venous thromboembolism, hormonal therapy and thrombosis, prevention of venous thrombosis in medical patients, and clinical practice guideline development.Dr. Douketis is a Fellow of the Canadian Academy of Health Science,  Associate Editor of McMaster Textbook of Internal Medicine, Editor-in-Chief of Canadian Journal of General Internal Medicine, Deputy Editor of Annals of Internal Medicine ACP Journal Club, and Associate Editor of Thrombosis and Haemostasis. He has over 350 peer-reviewed publications.Related Thrombosis Canada Resources:DOAC Bleeding Management Clinical Guide:  [LINK]DOAC Perioperative Management Clinical Guide: [LINK]Perioperative Anticoagulant Algorithm: [LINK]Follow us on Twitter: @thrombosiscanReference:Abraham NS, Barkun AN, Sauer BG, Douketis J, Laine L, Noseworthy PA, Telford JJ, Leontiadis GI. American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period. Journal of the Canadian Association of Gastroenterology. 2022 Apr;5(2):100-1Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

In this episode have a conversation with Dr Michelle Sholzberg on her recent publication from the British Medical Journal entitled Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial (BMJ 2021; 375 doi: https://doi.org/10.1136/bmj.n2400) which was co-authored by an international team on behalf of the RAPID trial investigators.Dr. Sholzberg received her MDCM and residency training in Internal Medicine at McGill University, completed additional postgraduate training in Hematology at the University of Toronto and a research hemostasis fellowship in Toronto and internationally. Dr. Sholzberg has a Master of Science from the University of Toronto in Clinical Epidemiology and Health Care Research and was awarded the Claire Bombardier award for career promise as a scientist. She is a clinician-investigator with a focus on coagulation, the Division Head of Hematology-Oncology and the Medical Director of the Coagulation Laboratory at St. Michael's Hospital. She is also the Director of the Hematology-Oncology Clinical Research Group and Co-director of the Hematology-Immunology Translational Research Theme of the Li Ka Shing Knowledge Institute. Dr. Sholzberg is the associate editor for illustrated materials at Research and Practice in Thrombosis and Haemostasis. Currently, she is involved in the study of: prediction tools for perioperative and traumatic bleeding, the intersection of women's health and bleeding disorders, treatments for iron deficiency anemia, new treatments for immune thrombocytopenia and the management of COVID-19 coagulopathy. Follow us on Twitter:Dr Michelle Sholzberg: @sholzbergThrombosis Canada: @ThrombosisCan Reference:Sholzberg M, Tang GH, Rahhal H, AlHamzah M, Kreuziger LB, Áinle FN, Alomran F, Alayed K, Alsheef M, AlSumait F, Pompilio CE. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ. 2021 Oct 14;375.  Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Welcome to Episode 6 of CLOT Conversations from Thrombosis Canada. In this episode Dr Jameel Abdulrehman and David Airdrie are joined by Dr Gregoire Le Gal and Dr Marc Carrier, two of the authors of a recently published paper on the entitled Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation. The paper was published in the Annals of internal medicine, 175(1), 29-35 https://www.acpjournals.org/doi/10.7326/M21-2981The authors discuss the results of the The SubSegmental Pulmonary Embolism (SSPE) study which was a prospective international multicenter management cohort study. The objective was to assess the rate of recurrent venous thromboembolism in patients with single or multiple isolated subsegmental pulmonary embolism without proximal deep venous thrombosis that was managed without anticoagulation. Dr. Grégoire Le Gal, is a Professor in the Department of Medicine at the University of Ottawa, the lead of the Thrombosis Program, Division of Hematology at Ottawa Hospital, and a Senior Scientist in the Ottawa Hospital Research Institute, Clinical Epidemiology Program since July 2012. He was born and trained in France. His primary research interest is the diagnosis and management of venous thromboembolism (VTE). He has 425 peer-reviewed publications in general internal medicine and specialized journals. He is the current chair of INVENT, the International Network of Venous Thromboembolism Clinical Research Networks.AndDr. Marc Carrier, the Head of the Division of Hematology at The Ottawa Hospital, a Professor in the Faculty of Medicine, Department of Medicine and Senior Scientist in the Clinical Epidemiology Program of The Ottawa Hospital Research Institute. He holds a Tier 1 Research Chair in Venous Thromboembolism and Cancer from the Faculty of Medicine at the University of Ottawa. Dr. Carrier is also president of Thrombosis Canada.See also: Thrombosis Canada Tools related to the content:Pulmonary Embolism Diagnosis: https://thrombosiscanada.ca/wp-uploads/uploads/2021/11/4.-Pulmonary-Embolism-Diagnosis_14November2021.pdfPulmonary Embolism Treatment: https://thrombosiscanada.ca/wp-uploads/uploads/2021/10/5.-Pulmonary-Embolism-Treatment_27Sept2021.pdfPulmonary Embolism Management tool:https://thrombosiscanada.ca/tools/?calc=vivomap261Follow us on Twitter:Dr Grégoire Le Gal : @GrelegalDr Marc Carrier: @MarcCarrier1Thrombosis Canada: @ThrombosisCan Reference: Le Gal, G., Kovacs, M. J., Bertoletti, L., Couturaud, F., Dennie, C., Hirsch, A. M., ... & SSPE Investigators. (2022). Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation: A Multicenter Prospective Cohort Study. Annals of internal medicine, 175(1), 29-35.Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Welcome to Episode 5 of CLOT Conversations from Thrombosis Canada. In this episode Dr Jameel Abdulrehman and David Airdrie are joined by Dr PJ Devereaux and Dr M Marcucci, two of the authors of a recently published paper on the POISE-3 study entitled Tranexamic Acid in Patients Undergoing Noncardiac Surgery. The paper was published in the New England Journal of Medicine (New England Journal of Medicine. 2022 Apr. DOI: 10.1056/nejmoa2201171. https://www.nejm.org/doi/full/10.1056/NEJMoa2201171).The authors discuss the results of the international POISE-3 study where 9539 patients underwent randomization. Patients were assigned to receive tranexamic acid (1-g intravenous bolus) or placebo at the start and end of surgery. The primary efficacy outcome was life-threatening bleeding, major bleeding, or bleeding into a critical organ (composite bleeding outcome) at 30 days. Dr Devereaux and Dr Marcucci discuss the study design, primary outcome and safety results, and the implications of the study.Dr. Devereaux obtained his MD from McMaster University.  After medical school he completed a residency in internal medicine at the University of Calgary and a residency in cardiology at Dalhousie University.  He then completed a PhD in Clinical Epidemiology at McMaster University. Dr. Devereaux is a cardiologist, perioperative care physician, and clinical epidemiologist.  He is the Director of the Division of Perioperative Care at McMaster University.  He is a Senior Scientist and the Scientific Leader of the Anesthesiology, Perioperative Medicine, and Surgical Research Group at the Population Health Research Institute.  Dr. Devereaux is a full Professor in the Departments of Health Research Methods, Evidence, and Impact (HEI) and Medicine at McMaster University.  He is the President of the Society of Perioperative Research and Care. Dr. Devereaux has published >390 peer reviewed papers and >85 book chapters, editorials, and commentaries.  Dr. Devereaux has an h-index of 108 and 266,260 citations.  He has given >1000 lectures and research presentations in 41 countries.  Dr. Devereaux's research program focuses on medical complications during and after surgery.  Dr. Devereaux is supported by the McMaster University/Hamilton Health Sciences Chair in Perioperative Care.  Dr. Devereaux holds a Tier 1 Canadian Research Chair in Perioperative Medicine.Dr. Maura Marcucci is an Assistant Professor at the Department of Health Research Methods, Evidence, and Impact (HEI), and Department of Medicine at McMaster University. She is attending physician in the Divisions of General Internal Medicine (GIM) and Perioperative Care. She is the Research Director for the Division of GIM. She is a Scientist at the Population Health Research Institute (PHRI), working with the Anesthesiology, Perioperative Medicine, and Surgical Research Group. She is also part of the McMaster Institute for Research on Aging (MIRA), and member of the Scientific Medical Policy Committee of the American College of Physicians. Her main research focus is on cardiovascular and functional outcomes of older people undergoing noncardiac surgery, with a particular interest in perioperative neurocognitive disorders.Thrombosis Canada Tools related to the content:DOACs*: Management of Bleeding Clinical Guide: https://thrombosiscanada.ca/clinicalguides/#Perioperative Anticoagulant Algorithm: https://thrombosiscanada.ca/tools/?calc=perioperativeAnticoagSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

This is Episode 4 of CLOT Conversations from Thrombosis Canada. In this episode Dr Jameel Abdulrehman and David Airdrie are joined by Dr Vinai Bhagirath and Dr Sam Schulman, two of the authors of a recently published paper entitled Carbamazepine, phenytoin, and oral anticoagulants: Drug-drug interaction and clinical events in a retrospective cohort. The paper was published in Research and Practice in Thrombosis and Haemostasis (Res Pract Thromb Haemost. 2022;6:e12650. https://doi.org/10.1002/rth2.12650)The authors discuss the results of the retrospective cohort of patients taking carbamazepine or phenytoin with warfarin or DOACs. In particular, they explore whether there is a relationship between anticoagulant levels and thromboembolic events. Dr Schulman and Dr Bhagirath discuss their perspectives on the issues relevant to each type of anticoagulant when used in patients on anti-seizure medications and what their study added to the understanding of drug-drug interactions.Dr Sam Schulman graduated from Karolinska Institutet, Stockholm, Sweden in 1977 and has worked with coagulation disorders since 1984. Research activities have been clinical studies in venous thromboembolism, in hemophilia and bleeding. He has been a member of the Executive Committee of the World Federation of Hemophilia, was President for the XXV ISTH Congress, Toronto, 2015, is member of the ISTH Council and Treasurer. In 2017 he received Harold R. Roberts medal of the ISTH SSC. He is Director of the Thrombosis Service at Hamilton General Hospital and professor in Medicine at McMaster University, Hamilton, Canada, and at Department of Obstetrics and Gynaecology, The First I.M. Sechenov Moscow State Medical University, Moscow, Russia.Dr Vinai Bhagirath, is a Thrombosis physician at Hamilton Health Sciences and Assistant Professor of Medicine at McMaster University. His research interests include bleeding risk with anticoagulants and clinical measurement of DOAC drug levels. His quality improvement interests include optimization of medical therapy in peripheral artery disease and standardization of periprocedural management of antithrombotic medications. His educational activities include Directorship of Thrombosis Fellowship programs at McMaster, and he is co-chair of the upcoming 2022 THSNA Summit and chair of Thrombosis Canada's Continuing Professional Development committee.Thrombosis Canada Tools related to the content:DOAC Drug Interaction tool: https://thrombosiscanada.ca/wp-uploads/uploads/2021/09/DDI-Tool-Final-English.pdfThrombosis Canada Clinical Guides: https://thrombosiscanada.ca/clinicalguides/Follow us on Twitter: Thrombosis Canada: @ThrombosisCan Sam Schulman: @SamSchulman6Reference: Candeloro, M., Eikelboom, J. W., Chan, N., Bhagirath, V., Douketis, J. D., & Schulman, S. (2022). Carbamazepine, phenytoin, and oral anticoagulants: Drug‐drug interaction and clinical events in a retrospective cohort. Research and Practice in Thrombosis and Haemostasis, 6(2), e12650.Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

In this episode Dr Jameel Abdulrehman and David Airdrie are joined by Dr Yan Xu, one of the authors of a recently published review paper entitled Evaluation of definitions for oral anticoagulant-associated major bleeding: A population-based cohort study, co-authored by Yan Xu, Tara Gomes, Philip S. Wells, Priscila Pequeno, Ana Johnson, and Michelle Sholzberg. The paper was published in Thrombosis Research (Thrombosis Research 213 (2022) 57–64) available here: https://www.thrombosisresearch.com/article/S0049-3848(22)00055-X/fulltextDr Xu provides an overview of how the ISTH, BARC, and TIMI definitions for major bleeding on anticoagulation differ and the impact that has on research outcomes. His review explores the study results and what they may mean for future studies.Biography:Dr. Yan Xu, is a subspecialty fellow in Adult Thrombosis Medicine at the University of Ottawa, having completed his medical school at Queen's University, internal medicine training at the University of Toronto and hematology fellowship at The Ottawa Hospital. Yan's research interests involve the use of routine clinical data to better understand the safety of anticoagulant therapy, and how to optimally manage bleeding complications that arise from their use. His work has been supported by the Canadian Institutes of Health Research, the American Society of Hematology, and the CanVECTOR Network.Thrombosis Canada Tools related to the content:Bleed management algorithm: https://thrombosiscanada.ca/tools/?calc=vivomap271Clinical Guide: DOACs, Management of Bleeding: https://thrombosiscanada.ca/wp-uploads/uploads/2021/11/23.-DOACs-Management-Bleeding_29November2021-1.pdfFollow us on Twitter:Thrombosis Canada: @ThrombosisCanDr Yan Xu: @IMYanXuReference:  Yan Xu, Tara Gomes, Philip S. Wells, Priscila Pequeno, Ana Johnson, Michelle Sholzberg, Evaluation of definitions for oral anticoagulant-associated major bleeding: A population-based cohort study, Thrombosis Research, Volume 213, 2022, Pages 57-64.Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

In this episode we are joined by Dr Vicky Tagalakis and Dr Marc Carrier, two of the authors of a recently published review paper entitled Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus. The paper was published in Current Oncology (Curr. Oncol. 2021, 28, 5434–5451. https://www.mdpi.com/1718-7729/28/6/453). The authors speak about why this update was undertaken and discuss many of the challenging scenarios encountered with this patient group and the recommendations for managing them. Join us for this insightful discussion that can help you in managing patients with cancer at risk of thrombosis.Dr. Vicky Tagalakis, is an Associate Professor of Medicine at McGill University and an attending in the Department of Medicine of the Jewish General Hospital. She is Director of the Division of General Internal Medicine at McGill University. She is a Research Scientist in the Centre of Epidemiology and Community of Studies, Lady Davis Institute for Medical Research, Jewish General Hospital. She holds several peer-reviewed grants. She is Co-Lead of the Quality Improvement Platform of CanVECTOR), a CIHR funded national research network on venous thromboembolism (VTE).Dr. Marc Carrier, is the Head of the Division of Hematology at The Ottawa Hospital, a Professor in the Faculty of Medicine, Department of Medicine and Senior Scientist in the Clinical Epidemiology Program of The Ottawa Hospital Research Institute. He holds a Tier 1 Research Chair in Venous Thromboembolism and Cancer from the Faculty of Medicine at the University of Ottawa. Dr. Carrier is also president of Thrombosis Canada.Related Thrombosis Canada resources:Downloadable PDF Algorithm: https://thrombosiscanada.ca/cat-treatment-algorithm-2021/DOAC Drug-Drug-Interaction tool: Download HereThrombosis Canada Cancer-associated Thrombosis (CAT) Clinical Guide: Download HereThrombosis Canada Clinical Guides: Visit HereFor other relevant resources, education programs and patient materials visit https://thrombosiscanada.caSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Welcome to Episode 1 of CLOT Conversations from Thrombosis Canada. In this episode Dr Jameel Abdulrehman and David Airdrie are joined by Dr Sameer Parpia and Dr Kerstin De Wit,  two of the authors of a recently published paper entitled Diagnosis of deep vein thrombosis with D-dimer adjusted to clinical probability: prospective diagnostic management study. The paper was published in the British Medical Journal (BMJ 2022;376:e067378 https://www.bmj.com/content/376/bmj-2021-067378) earlier this year. The lead investigator was Dr Clive Kearon, who unfortunately passed away in 2020. The study was co-authored by a cross-Canada team of researchers. The authors discuss the study outcomes and their clinical relevance with the hosts in this 20 minute program.Kerstin de Wit trained in internal medicine, emergency medicine and research in the UK. She completed a Thrombosis Fellowship in Ottawa in 2013. Since then, she has worked in both emergency medicine and thrombosis. She leads a research program which focuses on the diagnosis of bleeding and clotting disorders in the emergency department, and is funded by CIHR Sameer Parpia is an Associate Professor in the Departments of Oncology and Health Research Methods, Evidence, and Impact at McMaster University. His interests and expertise are in the design, conduct, monitoring, statistical analysis and reporting of randomized clinical trials. As a senior biostatistician, he provides statistical and methodological leadership for clinical trials in thrombosis. Thrombosis Canada Tools related to the content:Wells Criteria calculator: https://thrombosiscanada.ca/tools/?calc=wellsDVTDVT Diagnosis Algorithm: https://thrombosiscanada.ca/tools/?calc=vivomap263Follow us on Twitter:Thrombosis Canada: @ThrombosisCanDr Sameer Parpia: @ParpiaSameerDr Kerstin De Wit: @kerstindewitSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

An introduction to CLOT Conversations a new podcast for healthcare professionals with interviews and discussions on advances in thrombosis management. Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada